Circulating tumour DNA (CtDNA) as a liquid biopsy for melanoma

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · see citing works

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · see citing works

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · see citing works

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067 · see citing works

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · see citing works

Genomic classification of cutaneous melanoma

Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151 · see citing works

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Hauschild, A., Grob, J., Демидов, Л. В., Jouary, T., Gutzmer, R., Millward, M. J., Rutkowski, P. L., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,975 · see citing works

Liquid biopsies come of age: Towards implementation of circulating tumour DNA

Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809 · see citing works

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · see citing works

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222 · see citing works

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220 · see citing works

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207 · see citing works

<i>TERT</i> Promoter Mutations in Familial and Sporadic Melanoma

Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., Kadel, S., Moll, I., Nagore, E., Hemminki, K., et al. (2013) · Science · doi:10.1126/science.1230062 · Cited by 1,799 · see citing works

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624 · see citing works

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Ribas, A., Puzanov, I. J., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,580 · see citing works

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6219 · Cited by 1,492 · see citing works

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy

Alix-Panabières, C., & Pantel, K. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1483 · Cited by 1,394 · see citing works

Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

Forshew, T., Murtaza, M., Parkinson, C., Gale, D. G., Tsui, D. W. Y., Kaper, F., Dawson, S., Piskorz, A., Jimenez‐Liñan, M., Bentley, D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003726 · Cited by 1,298 · see citing works

Targeted agents and immunotherapies: optimizing outcomes in melanoma

Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,243 · see citing works

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195 · see citing works

Non-Invasive Analysis of Acquired Resistance to Cancer Therapy By Sequencing of Plasma Dna

(2014) · Annals of Oncology · doi:10.1093/annonc/mdu312.5 · Cited by 1,174 · see citing works

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

García-Murillas, I., Schiavon, G., Weigelt, B., Ng, C. K. Y., Hrebien, S., Cutts, R. J., Cheang, M. C. U., Osin, P., Nerurkar, A. Y., Kozarewa, I., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab0021 · Cited by 1,155 · see citing works

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982 · see citing works

The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

Allen, E. M. V., Wagle, N., Sucker, A., Treacy, D. J., Johannessen, C. M., Goetz, E. M., Place, C. S., Taylor-Weiner, A. N., Whittaker, S. R., Kryukov, G. V., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0617 · Cited by 904 · see citing works

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

Mattos‐Arruda, L. D., Mayor, R., Ng, C. K. Y., Weigelt, B., Ricarte, F. M., Torrejon, D. Y., Oliveira, M., Arias, A., Raventós, C., Tang, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms9839 · Cited by 870 · see citing works

Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer

Tie, J., Kinde, I., Wang, Y., Wong, H., Roebert, J. K., Christie, M., TACEY, M. A., Wong, R., Singh, M., Karapetis, C. S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv177 · Cited by 632 · see citing works

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

Rizos, H., Menzies, A. M., Pupo, G. M., Carlino, M. S., Fung, C., Hyman, J., Haydu, L. E., Mijatov, B., Becker, T. M., Boyd, S. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3122 · Cited by 543 · see citing works

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

O'Day, S., Maio, M., Chiarion-Sileni, V., Gajewski, T., Pehamberger, H., Bondarenko, I., Queirolo, P., Lundgren, L., Mikhailov, S., Roman, L., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq013 · Cited by 506 · see citing works

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

Thress, K. S., Brant, R., Carr, T. H., Dearden, S. P., Jenkins, S. C., Brown, H. J., Hammett, T., Cantarini, M., & Barrett, J. C. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.10.004 · Cited by 491 · see citing works

Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer

Murtaza, M., Dawson, S., McNamara, K. L., Rueda, O. M., Provenzano, E., Grant, J. W., Chin, S., Tsui, D. W. Y., Marass, F., Gale, D. G., et al. (2015) · Nature Communications · doi:10.1038/ncomms9760 · Cited by 478 · see citing works

Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma

Ascierto, P. A., Minor, D. R., Ribas, A., Lebbé, C., O’Hagan, A., Arya, N., Guckert, M. E., Schadendorf, D., Kefford, R. F., Grob, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.8691 · Cited by 433 · see citing works

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle

Mattos‐Arruda, L. D., Weigelt, B., Cortés, J., Won, H. H., Ng, C. K. Y., Nuciforo, P. G., Bidard, F., Aura, C. M., Saura, C., Peg, V., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu239 · Cited by 386 · see citing works

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

Long, G. V., Fung, C., Menzies, A. M., Pupo, G. M., Carlino, M. S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J. F., Saw, R. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6694 · Cited by 375 · see citing works

Detection of T790M, the Acquired Resistance <i>EGFR</i> Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

Sundaresan, T. K., Sequist, L. V., Heymach, J. V., Riely, G. J., Jänne, P. A., Koch, W. H., Sullivan, J. P., Fox, D. B., Maher, R., Muzikansky, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1031 · Cited by 347 · see citing works

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

Gray, E. S., Rizos, H., Reid, A. L., Boyd, S. C., Pereira, M. R., Lo, J., Tembe, V., Freeman, J. B., Lee, J., Scolyer, R. A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5788 · Cited by 340 · see citing works

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

Lee, J. H., Long, G. V., Boyd, S., Lo, S., Menzies, A. M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R. A., Mann, G. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx026 · Cited by 333 · see citing works

Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study

Larkin, J., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Espinosa, E., Garbe, C., Chiarion‐Sileni, V., Gogas, H. J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70051-8 · Cited by 277 · see citing works

Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma

Maker, A. V., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Hughes, M. S., Yellin, M. J., Haworth, L. R., Levy, C. L., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000208259.73167.58 · Cited by 264 · see citing works

TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma

Griewank, K., Murali, R., Puig‐Butillé, J. A., Schilling, B., Livingstone, E., Potrony, M., Carrera, C., Schimming, T. T., Möller, I., Schwamborn, M., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju246 · Cited by 251 · see citing works

Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors

Sanmamed, M. F., Landazuri, S. F., Rodríguez, C., Zárate, R., Lozano, M. D., Zubiri, L., Perez‐Gracia, J. L., Martín‐Algarra, S., & González, Á. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.230235 · Cited by 245 · see citing works

Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients

Hoon, D. S. �., Spugnardi, M., Kuo, C. T., Huang, S. K., Morton, D. L., & Taback, B. (2004) · Oncogene · doi:10.1038/sj.onc.1207505 · Cited by 242 · see citing works

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma

Girotti, M. R., Gremel, G., Lee, R. J., Galvani, E., Rothwell, D. G., Virós, A., Mandal, A. K., Lim, K. H. J., Saturno, G., Furney, S. J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1336 · Cited by 230 · see citing works

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance

Zheng, D., Ye, X.-R., Zhang, M. Z., Sun, Y., Wang, J. Y., Ni, J., Zhang, H. P., Zhang, L., Luo, J., Zhang, J., et al. (2016) · Scientific Reports · doi:10.1038/srep20913 · Cited by 224 · see citing works

Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade

Lipson, E. J., Velculescu, V. E., Pritchard, T. S., Sausen, M., Pardoll, D. M., Topalian, S. L., & Diaz, L. A. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0042-0 · Cited by 216 · see citing works

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

Santiago-Walker, A., Gagnon, R., Mazumdar, J., Casey, M., Long, G. V., Schadendorf, D., Flaherty, K. T., Kefford, R. F., Hauschild, A., Hwu, P., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0321 · Cited by 209 · see citing works

Methylation of cell-free circulating DNA in the diagnosis of cancer

Warton, K., & Samimi, G. (2015) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2015.00013 · Cited by 183 · see citing works

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations

Tsao, S. C., Weiss, J. M., Hudson, C., Christophi, C., Cebon, J. S., Behren, A., & Dobrovic, A. (2015) · Scientific Reports · doi:10.1038/srep11198 · Cited by 173 · see citing works

Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer

Jamal‐Hanjani, M., Wilson, G. A., Horswell, S. D., Mitter, R., Sakarya, O., Constantin, T. P., Salari, R., Kırkızlar, E., Sigurjonsson, S., Pelham, R. J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw037 · Cited by 170 · see citing works

Predictive Utility of Circulating Methylated DNA in Serum of Melanoma Patients Receiving Biochemotherapy

Mori, T., O'Day, S. J., Umetani, N., Martinez, S. R., Kitago, M., Koyanagi, K., Kuo, C. T., Takeshima, T., Milford, R., Wang, H.-J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.9876 · Cited by 165 · see citing works

BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies

Spagnolo, F., Ghiorzo, P., Orgiano, L., Pastorino, L., Picasso, V., Tornari, E., Ottaviano, V., & Queirolo, P. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s39096 · Cited by 161 · see citing works

Acquired resistance to EGFR‐targeted therapies in colorectal cancer

Emburgh, B. O. V., Bianchi, A. S., Nicolantonio, F. D., Siena, S., & Bardelli, A. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.003 · Cited by 160 · see citing works

Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation

Skvortsova, T. E., RYKOVA, E. Y., TAMKOVICH, S. N., Bryzgunova, O. E., Starikov, A. V., Kuznetsova, N. P., Vlassov, V. V., & Laktionov, P. P. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603117 · Cited by 151 · see citing works

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors

Schreuer, M. S., Meersseman, G., Herrewegen, S. V. D., Jansen, Y. J. L., Chevolet, I., Bott, A., Wilgenhof, S., Seremet, T., Jacobs, B., Buyl, R., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0852-6 · Cited by 144 · see citing works

An Epigenetic Marker Panel for Detection of Lung Cancer Using Cell-Free Serum DNA

Begum, S., Brait, M., Dasgupta, S., Ostrow, K. L., ZAHURAK, M. L., Carvalho, A. L., Califano, J. A., Goodman, S. N., Westra, W. H., Hoque, M. O., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3436 · Cited by 137 · see citing works

TERT promoter mutations in melanoma survival

Nagore, E., Heidenreich, B., Rachakonda, P. S., García‐Casado, Z., Requena, C., Soriano, V., Frank, C., Traves, V., Quecedo, E., Sanjuan‐Gimenez, J., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30042 · Cited by 122 · see citing works

Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors

Liggett, T., Melnikov, A. A., Yi, Q., Replogle, C., Hu, W., Rotmensch, J., Kamat, A. A., Sood, A. K., & Levenson, V. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.09.019 · Cited by 118 · see citing works

Cell‐free DNA and RNA in Plasma as a New Molecular Marker for Prostate and Breast Cancer

Papadopoulou, E., Davilas, E., Sotiriou, V., Georgakopoulos, E., Georgakopoulou, S., Koliopanos, A., Aggelakis, F., Dardoufas, K., Agnanti, N., Karydas, I., et al. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1368.032 · Cited by 117 · see citing works

Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma

Wong, S. Q., Raleigh, J., Callahan, J., Vergara, I. A., Ftouni, S., Hatzimihalis, A., Colebatch, A. J., Li, J., Semple, T. J., Doig, K., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00009 · Cited by 114 · see citing works

Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR

Reid, A. L., Freeman, J. B., Millward, M. J., Ziman, M. R., & Gray, E. S. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.12.007 · Cited by 109 · see citing works

Association of Circulating Tumor Cells with Serum Tumor-Related Methylated DNA in Peripheral Blood of Melanoma Patients

Koyanagi, K., Mori, T., O'Day, S. J., Martinez, S. R., Wang, H.-J., & Hoon, D. S. �. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4198 · Cited by 100 · see citing works

Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients

Huang, S. K., & Hoon, D. S. �. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.008 · Cited by 99 · see citing works

Epigenetic Inactivation of Tumor Suppressor Genes in Serum of Patients with Cutaneous Melanoma

Marini, A., Mirmohammadsadegh, A., Nambiar, S., Gustrau, A., Ruzicka, T., & Hengge, U. R. (2005) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700073 · Cited by 98 · see citing works

Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients

Ponomaryova, A. A., RYKOVA, E. Y., Чердынцева, Н. В., Skvortsova, T. E., Dobrodeev, А. Y., Zav’yalov, A. A., Bryzgalov, L. O., Тузиков, С. А., Vlassov, V. V., & Laktionov, P. P. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.05.016 · Cited by 97 · see citing works

Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases

Li, Y., Pan, W., Connolly, I. D., Reddy, S. A., Nagpal, S., Quake, S. R., & Gephart, M. H. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2081-5 · Cited by 97 · see citing works

A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance

Wang, W., Song, Z., & Zhang, Y. (2016) · Cancer Medicine · doi:10.1002/cam4.978 · Cited by 93 · see citing works

Abstract CT082: Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of CheckMate 026

Peters, S., Creelan, B., Hellmann, M. D., Socinski, M. A., Reck, M., Bhagavatheeswaran, P., Chang, H., Geese, W. J., Paz-Ares, L. G., & Carbone, D. P. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct082 · Cited by 92 · see citing works

AIM1 and LINE-1 Epigenetic Aberrations in Tumor and Serum Relate to Melanoma Progression and Disease Outcome

Hoshimoto, S., Kuo, C. T., Chong, K. K., Takeshima, T., Takei, Y., Li, M. W., Huang, S. K., Sim, M., Morton, D. L., & Hoon, D. S. �. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.36 · Cited by 85 · see citing works

Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer

Balgkouranidou, I., Chimonidou, M., Milaki, G., Tsarouxa, E. G., Kakolyris, S., Welch, D. R., Georgoulias, V., & Lianidou, E. S. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.104 · Cited by 85 · see citing works

BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors

González‐Cao, M., Mayo‐de‐las‐Casas, C., Molina‐Vila, M. Á., Mattos‐Arruda, L. D., Muñoz‐Couselo, E., Manzano, J. L., Cortés, J., Berros, J. P., Drozdowskyj, A., Sanmamed, M. F., et al. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000187 · Cited by 79 · see citing works

Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients

Majchrzak‐Celińska, A., Paluszczak, J., Kleszcz, R., Magiera, M., Barciszewska, A., Nowak, S., & Baer‐Dubowska, W. (2013) · Journal of Applied Genetics · doi:10.1007/s13353-013-0149-x · Cited by 76 · see citing works

Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA

Hayashi, M., Chu, D. T. W., Meyer, C. F., Llosa, N. J., McCarty, G., Morris, C. D., Levin, A. S., Wolinsky, J., Albert, C. M., Steppan, D. A., et al. (2016) · Cancer · doi:10.1002/cncr.30144 · Cited by 76 · see citing works

Sensitivity of plasma BRAFmutant and NRASmutant cell‐free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non‐RECIST disease progression

Chang, G. A., Tadepalli, J. S., Shao, Y., Zhang, Y., Weiss, S. A., Robinson, E. M., Spittle, C., Furtado, M. R., Shelton, D. N., Karlin-Neumann, G. A., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.09.005 · Cited by 73 · see citing works

Methylation patterns in cell‐free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients

Liggett, T., Melnikov, A. A., Marks, J. R., & Levenson, V. (2010) · International Journal of Cancer · doi:10.1002/ijc.25363 · Cited by 68 · see citing works

Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies

Momtaz, P., Pentsova, E. I., Abdel-Wahab, O. I., Diamond, E. L., Hyman, D. M., Merghoub, T., You, D., Gasmi, B., Viale, A. J., & Chapman, P. B. (2016) · Oncotarget · doi:10.18632/oncotarget.13397 · Cited by 65 · see citing works

A SNP profiling panel for sample tracking in whole-exome sequencing studies

Pengelly, R. J., Gibson, J., Andreoletti, G., Collins, A. R., Mattocks, C., & Ennis, S. (2013) · Genome Medicine · doi:10.1186/gm492 · Cited by 63 · see citing works

Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma

Kristensen, L. S., Hansen, J. W., Kristensen, S. S., Tholstrup, D., Harsløf, L. B. S., Pedersen, O. B., Brown, P. D. N., & Grønbæk, K. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0261-y · Cited by 62 · see citing works

Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer

Bondurant, A., Huang, Z., Whitaker, R. S., Simel, L. R., Berchuck, A., & Murphy, S. K. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.08.029 · Cited by 61 · see citing works

Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer

Matthaios, D., Balgkouranidou, I., Karayiannakis, A. J., Bolanaki, H., Xenidis, N., Amarantidis, K., Chelis, L., Romanidis, Κ., Chatzaki, Ε., Lianidou, E. S., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.4649 · Cited by 55 · see citing works

TERT promoter mutations associate with fast‐growing melanoma

Nagore, E., Heidenreich, B., Requena, C., García‐Casado, Z., Martorell, A., Pont‐Sanjuan, V., Jiménez‐Sánchez, A. I., & Kumar, R. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12441 · Cited by 54 · see citing works

Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing

Li, Z., Guo, X., Tang, L., Peng, L., Chen, M., Luo, X., Wang, S., Xiao, Z. Q., Deng, Z., Dai, L., et al. (2016) · Tumor Biology · doi:10.1007/s13277-016-5190-z · Cited by 50 · see citing works

Use of cell free DNA in breast oncology

Canzoniero, J. V., & Park, B. H. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.03.006 · Cited by 49 · see citing works

Checkpoint Blockade for the Treatment of Advanced Melanoma

Callahan, M. K., Flaherty, C., & Postow, M. A. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_9 · Cited by 47 · see citing works

Tumor-Related Methylated Cell-Free DNA and Circulating Tumor Cells in Melanoma

Salvianti, F., Orlando, C., Massi, D., GIORGI, V. D., Grazzini, M., Pazzagli, M., & Pinzani, P. (2016) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2015.00076 · Cited by 39 · see citing works

Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline

Knol, A., Vallée, A., Herbreteau, G., Nguyen, J., Varey, É., Gaultier, A., Théoleyre, S., Saint-Jean, M., Peuvrel, L., Brocard, A., et al. (2016) · Experimental Dermatology · doi:10.1111/exd.13065 · Cited by 38 · see citing works

Methylation of RAR-β2, RASSF1A, and CDKN2A genes induced by nickel subsulfide and nickel-carcinogenesis in rats.

Zhang, J., Zhang, J., Li, M., Wu, Y., Fan, Y., Zhou, Y., Tan, L., Shao, Z., & Shi, H. (2011) · PubMed · doi:10.3967/0895-3988.2011.02.011 · Cited by 30 · see citing works

High TERT promoter mutation frequency in non‐acral cutaneous metastatic melanoma

Ekedahl, H., Lauss, M., Olsson, H. L., Griewank, K., Schadendorf, D., Ingvar, C., & Jonsson, G. G. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12500 · Cited by 26 · see citing works

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360 · see citing works

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

Weber, J. S., Carlino, M. S., Khattak, A., Meniawy, T., Ansstas, G., Taylor, M. H., Kim, K. B., McKean, M., Long, G. V., Sullivan, R. J., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02268-7 · Cited by 916 · see citing works

The emerging role of cell-free DNA as a molecular marker for cancer management

Bronkhorst, A. J., Ungerer, V., & Holdenrieder, S. (2019) · Biomolecular Detection and Quantification · doi:10.1016/j.bdq.2019.100087 · Cited by 566 · see citing works

Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine

Liang Cheng, C., Antonio Lopez-beltran, B., Massari, F., MacLennan, G. T., & Montironi, R. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.104 · Cited by 409 · see citing works

BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers

Castellani, G., Buccarelli, M., Arasi, M. B., Rossi, S., Pisanu, M. E., Bellenghi, M., Lintas, C., & Tabolacci, C. (2023) · Cancers · doi:10.3390/cancers15164026 · Cited by 188 · see citing works

Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAF V600E mutation

Garcı́a-Silva, S., Benito‐Martín, A., Sánchez‐Redondo, S., Hernández‐Barranco, A., Ximénez‐Embún, P., Nogués, L., Mazariegos, M. S., Brinkmann, K., López, A. A., Meyer, L., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181522 · Cited by 135 · see citing works

Evaluation of commercial kits for purification of circulating free DNA

Diefenbach, R. J., Lee, J., Kefford, R. F., & Rizos, H. (2018) · Cancer Genetics · doi:10.1016/j.cancergen.2018.08.005 · Cited by 129 · see citing works

Liquid biomarkers in melanoma: detection and discovery

Lim, S. Y., Lee, J., Diefenbach, R. J., Kefford, R. F., & Rizos, H. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0757-5 · Cited by 95 · see citing works

A supersensitive silicon nanowire array biosensor for quantitating tumor marker ctDNA

Li, D., Chen, H., Fan, K., Лабунов, В. А., Lazarouk, S. K., Yue, X., Liu, C., Yang, X., Dong, L., & Wang, G. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113147 · Cited by 87 · see citing works

Electrochemical affinity biosensors for fast detection of gene-specific methylations with no need for bisulfite and amplification treatments

Povedano, E., Vargas, E., Montiel, V. R., Torrente-Rodríguez, R. M., Pedrero, M., Barderas, R., Segundo‐Acosta, P. S., Peláez‐García, A., Mendiola, M., Hardisson, D., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24902-1 · Cited by 83 · see citing works

Circulating MicroRNA Biomarkers in Melanoma: Tools and Challenges in Personalised Medicine

Mumford, S., Towler, B. P., Pashler, A. L., Gilleard, O., Martin, Y., & Newbury, S. (2018) · Biomolecules · doi:10.3390/biom8020021 · Cited by 83 · see citing works

Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine

Tarhini, A. A., & Kudchadkar, R. R. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.005 · Cited by 82 · see citing works

Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer

Osumi, H., Shinozaki, E., Takeda, Y., Wakatsuki, T., Ichimura, T., Saiura, A., Yamaguchi, K., Takahashi, S., Noda, T., & Zembutsu, H. (2018) · Cancer Medicine · doi:10.1002/cam4.1913 · Cited by 80 · see citing works

Unraveling the Wide Spectrum of Melanoma Biomarkers

Revythis, A., Shah, S., Kutka, M., Moschetta, M., Öztürk, M. A., Pappas‐Gogos, G., Ioannidou, E., Sheriff, M., Rassy, E., & Boussios, S. (2021) · Diagnostics · doi:10.3390/diagnostics11081341 · Cited by 80 · see citing works

High-performance electrochemical sensing of circulating tumor DNA in peripheral blood based on poly-xanthurenic acid functionalized MoS2 nanosheets

Zhang, W., Dai, Z., Liu, X., & Yang, J. (2018) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2018.01.038 · Cited by 77 · see citing works

Rapid Electrochemical Assessment of Tumor Suppressor Gene Methylations in Raw Human Serum and Tumor Cells and Tissues Using Immunomagnetic Beads and Selective DNA Hybridization

Povedano, E., Valverde, A., Montiel, V. R., Pedrero, M., Yáñez‐Sedeño, P., Barderas, R., Segundo‐Acosta, P. S., Peláez‐García, A., Mendiola, M., Hardisson, D., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201804339 · Cited by 74 · see citing works

Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance

Hu, Z.-Y., Xie, N., Tian, C., Yang, X., Liu, L., Li, J., Xiao, H., Wu, H., Lü, J., Gao, J., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.05.015 · Cited by 72 · see citing works

Trends and perspectives in DNA biosensors as diagnostic devices

Kowalczyk, A. (2020) · Current Opinion in Electrochemistry · doi:10.1016/j.coelec.2020.03.003 · Cited by 66 · see citing works

Recent Advances and Emerging Trends in Cancer Biomarker Detection Technologies

Kumar, R. K. R., Kumar, A., Chuang, C.-H., & Shaikh, M. O. (2023) · Industrial & Engineering Chemistry Research · doi:10.1021/acs.iecr.2c04097 · Cited by 62 · see citing works

MALDI Detection of Exosomes: A Potential Tool for Cancer Studies

Zhu, Y., Pick, H. M., Gasilova, N., Li, X., Lin, T.-E. L., Laubli, H. P., Zippelius, A., Ho, P., & Girault, H. H. (2019) · Chem · doi:10.1016/j.chempr.2019.04.007 · Cited by 58 · see citing works

Serial ultra‐deep sequencing of circulating tumor DNA reveals the clonal evolution in non‐small cell lung cancer patients treated with anti‐PD1 immunotherapy

Li, L., Wang, Y., Shi, W., Zhu, M., Liu, Z., Luo, N., Zeng, Y., & He, Y. (2019) · Cancer Medicine · doi:10.1002/cam4.2632 · Cited by 53 · see citing works

A dual biomarker detection platform for quantitating circulating tumor DNA (ctDNA)

Cai, C., Guo, Z., Cao, Y., Zhang, W., & Chen, Y. (2017) · Nanotheranostics · doi:10.7150/ntno.22419 · Cited by 52 · see citing works

Locus‐specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma

Calapre, L., Giardina, T. M., Robinson, C., Reid, A. L., Al‐Ogaili, Z., Pereira, M. R., McEvoy, A. C., Warburton, L., Hayward, N. K., Khattak, M. A., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12391 · Cited by 49 · see citing works

Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma

Fattore, L., Ruggiero, C. F., Liguoro, D., Mancini, R., & Ciliberto, G. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2048-5 · Cited by 48 · see citing works

Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma

Boyer, M., Cayrefourcq, L., Dereure, O., Meunier, L., Becquart, O., & Alix‐Panabières, C. (2020) · Cancers · doi:10.3390/cancers12040960 · Cited by 48 · see citing works

Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells

Testa, U., Castelli, G., & Pelosi, E. (2017) · Medical Sciences · doi:10.3390/medsci5040028 · Cited by 48 · see citing works

Evaluating the cerebrospinal fluid ctDNA detection by next-generation sequencing in the diagnosis of meningeal Carcinomatosis

Zhao, Y., He, J., Zou, Y., Guo, X., Cui, J., Guo, L., & Bu, H. (2019) · BMC Neurology · doi:10.1186/s12883-019-1554-5 · Cited by 47 · see citing works

Silicon Nanowires and Their Impact on Cancer Detection and Monitoring

Smith, R., Geary, S. M., & Salem, A. K. (2020) · ACS Applied Nano Materials · doi:10.1021/acsanm.0c01572 · Cited by 46 · see citing works

Clinical protein science in translational medicine targeting malignant melanoma

Gil, J., Betancourt, L. H., Pla, I., Sanchez, A., Appelqvist, R., Miliotis, T., Kuras, M., Oskolas, H., Kim, Y., Horvath, Z., et al. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09468-6 · Cited by 45 · see citing works

S100-EPISPOT: A New Tool to Detect Viable Circulating Melanoma Cells

Cayrefourcq, L., de Roeck, A., Garcia, C. H., Stoebner, P., Fichel, F., Garima, F., Perriard, F., Daurès, J., Meunier, L., & Alix‐Panabières, C. (2019) · Cells · doi:10.3390/cells8070755 · Cited by 45 · see citing works

Cerebrospinal fluid biomarkers for brain tumor detection: clinical roles and current progress.

Xiao, F., Lv, S., Zong, Z., Wu, L., Tang, X., Kuang, W., Zhang, P., Li, X., Fu, J., Xiao, M., et al. (2020) · PubMed Central · Cited by 44 · see citing works

Non-invasive lung cancer diagnosis and prognosis based on multi-analyte liquid biopsy

Chen, K., Sun, J., Zhao, H., Jiang, R., Zheng, J., Li, Z., Peng, J., Shen, H., Zhang, K., Zhao, J., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01323-9 · Cited by 46 · see citing works

Rapid Electrochemical Assessment of Tumor Suppressor Gene Methylations in Raw Human Serum and Tumor Cells and Tissues Using Immunomagnetic Beads and Selective DNA Hybridization

Povedano, E., Valverde, A., Montiel, V. R., Pedrero, M., Yáñez‐Sedeño, P., Barderas, R., Segundo‐Acosta, P. S., Peláez‐García, A., Mendiola, M., Hardisson, D., et al. (2018) · Angewandte Chemie · doi:10.1002/ange.201804339 · Cited by 44 · see citing works

Ultrasensitive electrochemical immunoassay for melanoma cells using mesoporous polyaniline

Udayan, A. P. M., Rodríguez, C. I., Sadak, O., Guan, J., Setaluri, V., & Gunasekaran, S. (2017) · Chemical Communications · doi:10.1039/c7cc09248b · Cited by 44 · see citing works

Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring

Kamińska, P., Buszka, K., Zabel, M., Nowicki, M. O., Alix‐Panabières, C., & Budna, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189714 · Cited by 44 · see citing works

Metastatic Melanoma: Liquid Biopsy as a New Precision Medicine Approach

Ricciardi, E., Giordani, E., Ziccheddu, G., Falcone, I., Giacomini, P., Fanciulli, M., Russillo, M., Cerro, M., Ciliberto, G., Morrone, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044014 · Cited by 40 · see citing works

Advancements in Nanofiber-Based Electrochemical Biosensors for Diagnostic Applications

Iftikhar, F. J., Shah, A., Wali, Q., & Kokab, T. (2023) · Biosensors · doi:10.3390/bios13040416 · Cited by 40 · see citing works

Photoelectrochemical genosensors for the determination of nucleic acid cancer biomarkers

Bettazzi, F., & Palchetti, I. (2018) · Current Opinion in Electrochemistry · doi:10.1016/j.coelec.2018.07.001 · Cited by 39 · see citing works

Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.

Irizarry-Alvarado, J. M., Dwyer, J. P., Brumble, L. M., Álvarez, S., & Mendez, J. (2009) · PubMed · Cited by 39 · see citing works

Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients

Long-Mira, É., Ilié, M., Chamorey, E., Leduff-Blanc, F., Montaudié, H., Tanga, V., Allégra, M., Lespinet‐Fabre, V., Bordone, O., Bonnetaud, C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26343 · Cited by 34 · see citing works

ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab

Forthun, R. B., Hovland, R., Schuster, C., Puntervoll, H. E., Brodal, H. P., Namløs, H. M., Aasheim, L. B., Meza‐Zepeda, L. A., Gjertsen, B. T., Knappskog, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53917-5 · Cited by 34 · see citing works

Monitoring Melanoma Using Circulating Free DNA

Diefenbach, R. J., Lee, J., & Rizos, H. (2018) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0398-x · Cited by 34 · see citing works

The “-OMICS” facet of melanoma: Heterogeneity of genomic, proteomic and metabolomic biomarkers

Donnelly, D. M., Aung, P. P., & Jour, G. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.014 · Cited by 32 · see citing works

Circulating biomarkers predictive of tumor response to cancer immunotherapy

Lee, E. Y., & Kulkarni, R. P. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1659728 · Cited by 32 · see citing works

Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma

Warburton, L., Meniawy, T. M., Calapre, L., Pereira, M. R., McEvoy, A. C., Ziman, M. R., Gray, E. S., & Millward, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-75837-5 · Cited by 29 · see citing works

Melanoma-Derived Extracellular Vesicles: Focus on Their Proteome

Surman, M., Stępień, E. Ł., & Przybyło, M. (2019) · Proteomes · doi:10.3390/proteomes7020021 · Cited by 28 · see citing works

The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma

Paris, A., Tardif, N., Baietti, F. M., Berra, C., Leclair, H. M., Leucci, E., Galibert, M., & Corre, S. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215677 · Cited by 26 · see citing works

Somatic gene mutation signatures predict cancer type and prognosis in multiple cancers with pan-cancer 1000 gene panel

Wang, H., Liu, P., Yue, J., Jiang, W., Cui, Y., Ren, H., Wang, H., Zhuang, Y., Liu, Y., Jiang, D., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.11.022 · Cited by 27 · see citing works

Assessment of Circulating Nucleic Acids in Cancer: From Current Status to Future Perspectives and Potential Clinical Applications

Cirmena, G., Dameri, M., Ravera, F., Fregatti, P., Ballestrero, A., & Zoppoli, G. M. (2021) · Cancers · doi:10.3390/cancers13143460 · Cited by 27 · see citing works

Highly sensitive detection of DNA hypermethylation in melanoma cancer cells

Nesvet, J. C., Rizzi, G., & Wang, S. X. (2018) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2018.10.018 · Cited by 25 · see citing works

A multiparameter liquid biopsy approach allows to track melanoma dynamics and identify early treatment resistance

Scaini, M. C., Catoni, C., Poggiana, C., Pigozzo, J., Piccin, L., Leone, K., Scarabello, I., Facchinetti, A., Menin, C., Elefanti, L., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00567-0 · Cited by 24 · see citing works

The Multiple Potential Biomarkers for Predicting Immunotherapy Response—Finding the Needle in the Haystack

Adam, T., Becker, T. M., Chua, W. M., Bray, V., & Roberts, T. L. (2021) · Cancers · doi:10.3390/cancers13020277 · Cited by 25 · see citing works

Vorinostat in patients with resistant BRAF V600E mutated advanced melanoma: a proof of concept study

Huijberts, S. C. F. A., Wang, L., de Oliveira, R. L., Rosing, H., Nuijen, B., Beijnen, J. H., Bernards, R., Schellens, J. H. M., & Wilgenhof, S. (2020) · Future Oncology · doi:10.2217/fon-2020-0023 · Cited by 22 · see citing works

Hairy Cell Leukaemia

Cross, M., & Dearden, C. E. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00911-0 · Cited by 21 · see citing works

Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma

Rizk, E. M., Seffens, A., Trager, M. H., Moore, M. R., Geskin, L. J., Gartrell, R. D., Wong, W., & Saenger, Y. M. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00475-1 · Cited by 20 · see citing works

Multiple time points for detecting circulating tumor DNA to monitor the response to neoadjuvant therapy in breast cancer: a meta-analysis

Niu, S., Sun, T. C., Wang, M., Yao, L., He, T., Wang, Y., Zhang, H., Li, X., & Xu, Y. (2025) · BMC Cancer · doi:10.1186/s12885-025-13526-0 · Cited by 19 · see citing works

An update on methods for detection of prognostic and predictive biomarkers in melanoma

Adeuyan, O. O., Gordon, E. R., Kenchappa, D., Bracero, Y., Singh, A. P., Espinoza, G., Geskin, L. J., & Saenger, Y. M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1290696 · Cited by 19 · see citing works

The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies—Beyond BRAF Mutant Detection

Marsavela, G., Johansson, P. A., Pereira, M. R., McEvoy, A. C., Reid, A. L., Robinson, C., Warburton, L., Khattak, M. A., Meniawy, T. M., Amanuel, B., et al. (2020) · Cancers · doi:10.3390/cancers12123793 · Cited by 19 · see citing works

Liquid Biopsy as a Tool for Differentiation of Leiomyomas and Sarcomas of Corpus Uteri

Dvorská, D., Škovierová, H., Braný, D., Halášová, E., & Daňková, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153825 · Cited by 18 · see citing works

Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma

Diefenbach, R. J., Lee, J., Strbenac, D., Yang, J. Y. H., Menzies, A. M., Carlino, M. S., Long, G. V., Spillane, A. J., Stretch, J. R., Saw, R. P. M., et al. (2019) · Cancers · doi:10.3390/cancers11121905 · Cited by 18 · see citing works

Promising clinical application of ctDNA in evaluating immunotherapy efficacy.

Li, L., Zhang, J., Jiang, X., & Li, Q. (2018) · Europe PMC (PubMed Central) · Cited by 16 · see citing works

Circulating tumour DNA as a cancer biomarker

Duffy, M. J. (2018) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563218798401 · Cited by 16 · see citing works

Biomedical overview of melanin. 1. Updating melanin biology and chemistry, physico-chemical properties, melanoma tumors, and photothermal therapy

BL罿QUEZ-CASTRO, A., & STOCKERT, J. C. (2021) · Biocell · doi:10.32604/biocell.2021.015900 · Cited by 16 · see citing works

Cell-Free DNA Diagnostics: Current and Emerging Applications in Oncology

Muluhngwi, P., Valdes, R., Fernandez-Botrán, R., Burton, E., Williams, B. J., & Linder, M. W. (2019) · Pharmacogenomics · doi:10.2217/pgs-2018-0174 · Cited by 16 · see citing works

Blood-Based Detection of BRAF V600E in Gliomas and Brain Tumor Metastasis

Kang, K. M., Muralidharan, K., Yekula, A., Small, J. L., Rosh, Z. S., Jones, P. S., Carter, B. S., & Balaj, L. (2021) · Cancers · doi:10.3390/cancers13061227 · Cited by 16 · see citing works

Circulating cell‐free high mobility group AT‐hook 2 mRNA as a detection marker in the serum of colorectal cancer patients

Sahengbieke, S., Wang, J., Li, X., Wang, Y., Lai, M., & Wu, J. (2017) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22332 · Cited by 15 · see citing works

Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis

Zheng, Y., Sun, H., Cong, L., Liu, C., Sun, Q., Wu, N., & Cong, X. (2021) · Journal of Oncology · doi:10.1155/2021/6660571 · Cited by 15 · see citing works

Electrochemical Sensing of Cancer‐related Global and Locus‐specific DNA Methylation Events

Campuzano, S., & Pingarrón, J. M. (2018) · Electroanalysis · doi:10.1002/elan.201800004 · Cited by 15 · see citing works

Promising Blood-Based Biomarkers for Melanoma: Recent Progress of Liquid Biopsy and Its Future Perspectives

Kanemaru, H., Mizukami, Y., Kaneko, A., Kajihara, I., & Fukushima, S. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00948-2 · Cited by 15 · see citing works

Construction of broom-like Ag@N,O-C sensing interface for electrochemical detection of circulating tumor DNA using entropy-driven DNA walker

Li, Q., Han, X., Feng, Q., & Wang, P. (2022) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2022.133157 · Cited by 14 · see citing works

Liquid biopsy-based analysis by ddPCR and CAPP-Seq in melanoma patients

Kaneko, A., Kanemaru, H., Kajihara, I., Myangat, T. M., Miyauchi, H., Kuriyama, H., Kimura, T., Sawamura, S., Makino, K., Miyashita, A., et al. (2021) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2021.04.006 · Cited by 14 · see citing works

Detection of cell‐free circulating BRAF V 600E by droplet digital polymerase chain reaction in patients with and without melanoma under dermatological surveillance

Calbet‐Llopart, N., Potrony, M., Tell‐Martí, G., Carrera, C., Barreiro, A., Aguilera, P., Podlipnik, S., Puig, S., Malvehy, J., & Puig‐Butillé, J. A. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18147 · Cited by 13 · see citing works

Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies

Clark, M. E., Rizos, H., Pereira, M. R., McEvoy, A. C., Marsavela, G., Calapre, L., Meehan, K. L., Ruhen, O., Khattak, M. A., Meniawy, T. M., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27790 · Cited by 13 · see citing works

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAF V600 -Mutated Melanoma

Embaby, A., Huijberts, S. C. F. A., Wang, L., de Oliveira, R. L., Rosing, H., Nuijen, B., Sanders, J., Hofland, I., van Steenis, C., Kluin, R. J. C., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3171 · Cited by 12 · see citing works

Validation of Circulating Tumor DNA Assays for Detection of Metastatic Melanoma

Syeda, M. M., Wiggins, J. M., Corless, B. C., Spittle, C., Karlin-Neumann, G. A., & Polsky, D. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_7 · Cited by 12 · see citing works

Tungsten disulfide nanosheets supported poly(xanthurenic acid) as a signal transduction interface for electrochemical genosensing applications

Yang, J., Yin, X., Xia, M., & Zhang, W. (2018) · RSC Advances · doi:10.1039/c8ra08669a · Cited by 11 · see citing works

Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report

Calapre, L., Warburton, L., Millward, M., & Gray, E. S. (2019) · BMC Cancer · doi:10.1186/s12885-019-6336-3 · Cited by 11 · see citing works

Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA

He, K., Zhang, S., Shao, L. L., Yin, J. C., Wu, X., Shao, Y. W., Yuan, S., & Yu, J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.12.004 · Cited by 9 · see citing works

Circulating Tumour DNAs and Non-Coding RNAs as Liquid Biopsies for the Management of Colorectal Cancer Patients

Lampis, A., Ghidini, M., Ratti, M., Mirchev, M. B., Okuducu, A. F., Valeri, N., & Hahne, J. C. (2020) · Gastrointestinal Disorders · doi:10.3390/gidisord2030022 · Cited by 10 · see citing works

Circulating tumor DNA monitoring in advanced mutated melanoma (LIQUID-MEL)

Martines, G., Carolina, P., Gregorio, M. J. C., Verzè, M., Pluchino, M., Claire, G. G., Michele, M., Giulia, M., Manuguerra, R., Azzoni, C., et al. (2025) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2025.100295 · Cited by 8 · see citing works

Longitudinal Relationship between Idylla Plasma ctBRAF V600 Mutation Detection and Tumor Burden in Patients with Metastatic Melanoma

Linder, M. W., Egger, M. E., Meter, T. L. V., Rai, S. N., Valdes, R., Hall, M. B., Wu, X., Alghamdi, N. J., & Chesney, J. A. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00528-4 · Cited by 7 · see citing works

Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients

Warburton, L., Reid, A. L., Amanuel, B., Calapre, L., Millward, M., & Gray, E. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1280730 · Cited by 7 · see citing works

Hypermethylation of Circulating Free DNA in Cutaneous Melanoma

Diefenbach, R. J., Lee, J., Chandler, D., Wang, Y., Pflueger, C., Long, G. V., Scolyer, R. A., Carlino, M. S., Menzies, A. M., Kefford, R. F., et al. (2019) · Applied Sciences · doi:10.3390/app9235074 · Cited by 7 · see citing works

US physician perspective on the use of biomarker and ctDNA testing in patients with melanoma

Fischer, R. A., Ryan, I., Torre, K. D. L., Barnett, C., Sehgal, V. S., Levy, J. B., Luke, J. J., Poklepovic, A. S., & Hurlbert, M. S. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104289 · Cited by 6 · see citing works

Microarray-based analysis of the BRAF V600 mutations in circulating tumor DNA in melanoma patients

Emelyanova, M., Телышева, Е. Н., Орлова, К. В., Ryabaya, O. O., Snigiryova, G. P., Abramov, I. S., & Mikhailovich, V. M. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.11.005 · Cited by 6 · see citing works

Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment

Carreira, B., Acúrcio, R. C., Matos, A. I., Peres, C., Pozzi, S., Vaskovich‐Koubi, D., Kleiner, R., Bento, M., Satchi‐Fainaro, R., & Florindo, H. F. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000147 · Cited by 6 · see citing works

Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach

Catoni, C., Poggiana, C., Facchinetti, A., Pigozzo, J., Piccin, L., Chiarion‐Sileni, V., Rosato, A., Minervini, G., & Scaini, M. C. (2022) · Cancers · doi:10.3390/cancers14174153 · Cited by 6 · see citing works

Circulating Tumor Cells in Cancer Diagnosis, Therapy, and Theranostics Applications: An Overview of Emerging Materials and Technologies

Soleymani, S., Naghib, S. M., & Mozafari, M. R. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128328459241009191933 · Cited by 5 · see citing works

The Role of Dynamic ctDNA Monitoring During Combination Therapies of BRAF V600E-Mutated Metastatic Colorectal Cancer: A Case Report

Wang, Z., Ye, C.-Y., Zhou, W., Wang, M., Dai, W.-P., Zheng, J., & Zang, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s265725 · Cited by 5 · see citing works

Liquid biopsy: the current state of the issue

Pasechnikova, E. A., Bodnya, V. N., Викторович, Ш. С., Kadomtsev, D. V., Georgieva, A. Y., & Stukan, А. I. (2021) · Innovative medicine of Kuban · doi:10.35401/2500-0268-2021-23-3-57-63 · Cited by 5 · see citing works

Clinicopathologic models predicting non‐sentinel lymph node metastasis in cutaneous melanoma patients: Are they useful for patients with a single positive sentinel node?

Rentroia‐Pacheco, B., Tjien-Fooh, F. J., Quattrocchi, E., Kobic, A., Wever, R., Bellomo, D., Meves, A., & Hieken, T. J. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26736 · Cited by 5 · see citing works

Haar Wavelet Pyramid-Based Melanoma Skin Cancer Identification With Ensemble of Machine Learning Algorithms

Thepade, S. D., & Ramnani, G. (2021) · International Journal of Healthcare Information Systems and Informatics · doi:10.4018/ijhisi.20211001.oa24 · Cited by 4 · see citing works

Detection of Gene Mutations in Liquid Biopsy of Melanoma Patients: Overview and Future Perspectives

Alrabadi, N., Haddad, R. H., & Alomari, A. K. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-0708-4 · Cited by 4 · see citing works

Characterization and Clinical Utility of BRAFV600 Mutation Detection Using Cell-Free DNA in Patients with Advanced Melanoma

Rutkowski, P. L., Pauwels, P., Kerger, J. N., Jacobs, B., Maertens, G. G., Gadeyne, V., Thielemans, A., de Backer, K., & Neyns, B. (2021) · Cancers · doi:10.3390/cancers13143591 · Cited by 4 · see citing works

Impact of genomics on the surgical management of melanoma

Ferguson, P. M., Long, G. V., Scolyer, R. A., & Thompson, J. F. (2018) · British journal of surgery · doi:10.1002/bjs.10751 · Cited by 3 · see citing works

Recent advances in plasmonics for liquid biopsy: A short review

Mitra, S. (2024) · Materials Today Communications · doi:10.1016/j.mtcomm.2024.109432 · Cited by 2 · see citing works

Liquid biopsy in clinical practice: current evidence and future directions

Chenchula, S., Paraskar, G., Krishna, S., & Chavan, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27496-1.00010-5 · Cited by 2 · see citing works

An Update Regarding the Molecular Genetics of Melanocytic Neoplasms and the Current Applications of Molecular Genetic Technologies in Their Diagnosis and Treatment

Kiavash, K., Bluth, M. H., & Thompson, A. D. (2018) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2018.02.002 · Cited by 2 · see citing works

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples

Gumà, J., Peña, K. B., Riu, F., Guilarte, C., Hernández‐Aguilera, A., Lucia-Gozalvez, C., Martínez-Madueño, F., Miranda, M. J., Cabezas, I., Grifoll, M., et al. (2022) · Cancers · doi:10.3390/cancers14235859 · Cited by 2 · see citing works

Using liquid biopsies to guide treatment and monitor response in BRAF V600E positive adenocarcinoma of unknown primary

Papayanis, P., Au, C., Jelinek, M. J., & Tan, A. (2025) · BMJ Case Reports · doi:10.1136/bcr-2024-264469 · Cited by 1 · see citing works

Circulating Tumor DNA in Melanoma: Advances in Detection, Clinical Applications, and Integration with Emerging Technologies

Charbel, N., Rizkallah, J., Bal, M., Masri, A. E., Armache, E., Ghezzawi, M., Awada, A., Kreidieh, L., Mehdi, J., & Kreidieh, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031569 · Cited by 10 · see citing works

Circulating Tumor DNA as a Biomarker for Melanoma Prognosis and Therapy

Heidrich, I., Urhahn, S., Gebhardt, C., Smit, D. J., & Pantel, K. (2026) · American Journal of Clinical Dermatology · doi:10.1007/s40257-026-01056-9 · Cited by 1 · see citing works

Assessment of the clinical validity of ctDNA Analysis for melanoma management

Marsavela, A.-G. (2021) · Australasian Journal of Paramedicine

Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions

Pikturnienė, R., Česas, A., Jarmalaitė, S., Razbadauskas, A., & Urbonas, V. (2024) · Cancers · doi:10.3390/cancers16061197 · Cited by 16 · see citing works

Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications

Busser, B., Lupo, J., Sancey, L., Mouret, S., Faure, P., Plumas, J., Chaperot, L., Leccia, M. ‐., Coll, J., Hurbin, A., et al. (2017) · BioMed Research International · doi:10.1155/2017/5986129 · Cited by 55 · see citing works